SGLT2 inhibitors × cardiac & vascular function

TrialNature medicine2022

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.

John A Spertus et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 476 people · 2022

Not counted

Probably raised cardiac & vascular function

+4.30points+0.80 to +7.80

As reported

difference 4.3 points, 95% CI 0.80–7.80

One number in the abstract

the abstract, start to end

The 12-week change in KCCQ TSS was 4.3 points (95% confidence

← favours treatmentfavours comparator →
could be chance
Cardiac & vascular function
4.30.80–7.80
SGLT2 inhibitorsCardiac & vascular function
1 / 3

138 papers cite itlatest 60 shown

2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 35228753